公开(公告)号：US20110212980A1

公开(公告)日：2011-09-01

申请号：US13125331

申请日：2009-10-21

申请人： Graeme Bilbe ,  Baltazar Gomez-Mancilla ,  Daniel Hoyer ,  Donald Johns ,  Hans O. Kalkman ,  Kevin Hall Mcallister

发明人： Graeme Bilbe ,  Baltazar Gomez-Mancilla ,  Daniel Hoyer ,  Donald Johns ,  Hans O. Kalkman ,  Kevin Hall Mcallister

IPC分类号： A61K31/517 ,  A61P25/06

CPC分类号： A61K31/4045 ,  A61K31/404 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/517 ,  A61K2300/00

摘要： The present invention relates to novel combinations suitable for the treatment of migraine of various genesis or aetiology, which comprise, as active ingredients, at least one 5-HT1 B/1 D receptor agonist and at least one selective, competitive AMPA receptor antagonist being a 1 H-quinazoline-2,4-dione of formula (I) as defined in the claims; to their preparation; to their use as medicaments and to medicaments comprising them.

摘要翻译： 本发明涉及适用于治疗各种发病或病因偏头痛的新型组合物，其包含作为活性成分的至少一种5-HT 1B / 1D受体激动剂和至少一种选择性竞争性AMPA受体拮抗剂，其为 如权利要求中定义的式（I）的1H-喹唑啉-2,4-二酮; 准备; 用作药物和包含它们的药物。

公开(公告)号：US20100063029A1

公开(公告)日：2010-03-11

申请号：US12616192

申请日：2009-11-11

申请人： Graeme Bilbe ,  John F. Cryan ,  Conrad Gentsch ,  Kevin Hall Mcallister ,  Markus Schmutz ,  Annick Vassout

发明人： Graeme Bilbe ,  John F. Cryan ,  Conrad Gentsch ,  Kevin Hall Mcallister ,  Markus Schmutz ,  Annick Vassout

IPC分类号： A61K31/55 ,  A61P25/00

CPC分类号： A61K31/55

摘要： The present invention relates to the use of a racemate of the compound of formula (I) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said anantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders.

摘要翻译： 本发明涉及由至少85％S-对映体和不超过15％R-对映异构体或所述外消旋物或S-对映异构体的药学上可接受的盐组成的式（I）化合物的外消旋体的用途 式I的药学上可接受的盐或所述对映异构体的药学上可接受的盐，用于治疗焦虑症或具有潜在焦虑症状学的其他精神疾病或用于治疗情感和注意力障碍; 用于该目的的药物组合物和包含所述药物组合物的包装以及使用所述组合物治疗焦虑症或其他具有潜在焦虑症状或精神障碍的精神疾病的说明书。